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 Port wine stains are capillary malformations that are typically located in the 
dermis of the head and neck.  They affect 0.3% of the population.  Current theories 
suggest that port wine stains are caused by somatic mutations that disrupt vascular 
development.  I hypothesize that port wine stains are multifactorial and understanding 
their genetic determinants could provide insight into novel treatments.  This study used a 
custom next generation sequencing panel and digital polymerase chain reaction to 
investigate genetic variants in 12 isolated port wine stain cases (i.e., individuals with port 
wine stain alone).  Novel variants were identified in GNAQ, SOX10, and RASA1.  The 
previously identified GNAQ c.548G>A, p.Arg183Gln mutation was confirmed in 9 of 12 
cases with an allele frequency ranging from 1.73 to 7.42%.  The custom next generation 
sequencing panel allowed for detection of low level mosaicism found in 10 of 12 isolated 
port wine stain cases. A novel GNAQ c.547C>G, p.Arg183Gly mutation was identified in 
one case. Digital polymerase chain reaction confirmed novel variants detected by next 
generation sequencing.  The results from both methods were highly concordant providing 
an effective way to detect low level mosaicism in port wine stains.  Importantly, the 
identification of novel genetic mutations in port wine stains may facilitate the 
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 Vascular anomalies are a group of disorders represented by abnormal 
development of blood vessels. These disorders are classified into either vascular tumors 
or vascular malformations according to the International Society for the Study of 
Vascular Anomalies (ISSVA) guidelines (Lowe, Marchant, Rivard, & Scherbel, 2012). 
Vascular malformations are further divided depending on the type of vessel affected. Port 
wine stains (PWS, OMIM 163000) are abnormal development of the capillary vessels, 
also called capillary malformation (CM).  
PWS are present at birth as a pink, well-marked patch that will gradually thicken 
and darken over time. They are more common on the face and neck, but do occur in other 
locations. Histology describes PWS as dilated capillary-like vessels with normal 
endothelial cells and decreased neuronal markers (Smoller & Rosen, 1986). Most cases of 
PWS are isolated, but recently Rubin et al. (2015) has reported familial cases. Port wine 
stains are present in 3 of 1,000 individuals (Jacobs & Walton, 1976). 
The etiology of PWS is unclear, but one theory suggests that they are caused by a 
somatic mutation that disrupts early vascular development (Happle, 1987). Shirley et al. 
(2013) was able to confirm this theory with the identification of a somatic mutation in 
GNAQ (c.548G>A, p.Arg183Gln) in 12 of 13 isolated PWS cases. GNAQ is a guanine 






Another theory I suggest is that port wine stains are caused by a somatic event 
that occurred during neural crest cell development and specialization. SOX10 is a  
transcription factor that is necessary for specific cell fates during neural crest 
development. PAX3 is another transcription factor that is crucial for neural crest cell 
development. Mutations in SOX10 and PAX3 have been reported in cases of 
Waardenburg syndrome, which results in sensorineural deafness and pigmentation 
defects (Bondurand et al., 2000).  
Mutations in RASA1 have been identified in cases of capillary malformation-
arteriovenous malformation (CM-AVM; OMIM 608354) (Eerola, et al., 2003). CM-
AVM is a familial vascular malformation syndrome that is also associated with high-flow 
arteriovenous malformations (AVM) or arteriovenous fistulas (AVF), or Parkes-Weber 
syndrome (PKWS; OMIM 608355) (Boon, Mulliken, & Vikkula, 2005; Frigerio, 
Stevenson, & Grimmer, 2012 ). RASA1 is a p120-RasGAP that reverts active GTP-bound 
RAS to its inactive GDP-bound form to control cell differentiation and proliferation 
(Eerola, et al., 2003). Recently, Revencu et al. (2013) identified a somatic second-hit 
RASA1 mutation in the dermal lesion of a CM-AVM patient. 
 The current treatment for PWS is pulsed dye laser (PDL) in combination with 
epidermal cooling, which lightens the vascular lesion in most cases (Kelly et al., 2005). 
However, there are a number of cases that respond very little, or not at all, to PDL 
treatment. Understanding the molecular background of PWS could potentially lead to 
more effective treatments. 
 This study was designed to investigate additional genetic variants and confirm the 
previously identified GNAQ c.548G>A, p.Arg183Gln in patients with isolated PWS. This  
 
 





was done using a six gene custom capture next generation sequencing (NGS) panel that is 
able to detect low level mosaicism, ~0.1% (Wooderchak-Donahue et al., 2012). Digital 
polymerase chain reaction (dPCR) was used to confirm suspected variants identified by 
the custom NGS panel.  
The majority of genes represented a variety of diseases that were either already 
associated with a CM or causative of other vascular malformations (Table 1). GNAQ, 
RASA1, and SOX10 were included along with; GLMN, TIE2/TEK, and PAX3. GLMN and 
TIE2/TEK are both associated with venous malformations. Like SOX10, PAX3 was 


















Disease  Exons 






activity,               
 Potential protein 
deficiency 
7 






Capillary malformations,             
Sturge-Weber syndrome,               
Parkes-Weber Syndrome,  
25 
SOX10 22q13.1 NM_006941 
SRY (sex 
determining 
region Y) box 
10 
Waardenburg syndrome 4 
PAX3 2q35 NM_181458 Paired box 3 Waardenburg syndrome 10 
TIE2/TEK 9p21 NM_000459 
TEK tyrosine 
kinase 
Venous malformations 23 















MATERIALS AND METHODS 
 
Sample Collection 
Participants were recruited from adult patients who entered the Carolyn and Peter 
Lynch Laser Center at Massachusetts Eye and Ear Infirmary (MEEI) for treatment of 
their PWS. Individuals who met the following exclusion criteria were not included in the 
study: cognitively, visually, or hearing impaired persons; pregnant women; non-English 
speakers; individuals with associated venous or lymphatic malformations.  
Eleven females and 1 male, ranging 18-72 years, were enrolled in the study. All 
PWS were isolated cases, i.e., not associated with any other vascular malformation. PWS 
were phenotyped using 3dMD photogrammetric software (3dMD; Atlanta, GA) 
according to a method previously described (Frigerio et al., 2014). Patient demographics 
and location of PWS are detailed in Table 2.  
Two, 3 mm punch, skin samples were collected from each participant. One intra-
lesional biopsy was performed on PWS skin and a second on apparently normal skin of 
the contralateral, corresponding body region. For each sample, a small part was formalin-
fixed, paraffin embedded for histological staining. The remainder of the sample was flash 
frozen and stored at -80°C. Samples were shipped overnight on dry ice to ARUP 
Laboratories, University of Utah, Salt Lake City, UT, for DNA extraction and analysis. 
DNA from an unaffected female peripheral blood sample was used as a negative control.  





Table 2.  Patient demographics and PWS location 
 
Case # Sex Age (years) PWS location 
Side                     
(R:right; 
L:left) 
1 M 41 V2 dermatome L 
2 F 39 upper body L 
3 F 72 Wrist R 
4 F 29 V1 dermatome L 
5 F 18 V3 dermatome;  C2 dermatome R,L ; R 
6 F 33 upper body R,L 
7 F 62 V2 dermatome; V3 dermatome L ; R,L 
8 F 28 half body R,L 
9 F 26 Shin R 
10 F 25 V1 dermatome L 
11 F 51 Forearm L 
12 F 45 V2 dermatome R 
Dermatome is an area of skin that is supplied by a single spinal nerve. V1,V2, V3 refers 
to the trigeminal nerve (fifth cranial nerve). C2 is the cervical vertebrae location. 
 
 
Helsinki protocols were followed and written. Institutional review board approval was 
obtained by MEEI Human Studies Committee (IRB # 12-120H) and by the University of 
Utah Institutional Review Board (IRB # 00059017).  
 
Tissue Sample Processing 
DNA was extracted from 12 affected tissue samples and 12 unaffected tissue 
samples using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD) protocol 
with a three day proteinase K incubation at 56° C. DNA concentrations were verified 





NGS Custom Capture 
Custom capture RNA baits were designed to target the exons and exon/intron 
boundaries of the six genes in Table 1 (~0.04Mb). DNA from affected and control tissue 
(1.4-3µg) were sheared to 180 bp fragments using a Covaris instrument (Covaris, 
Woburn, MA).  Illumina adapters were added using the SureSelect XT kit reagents 
(Agilent Technologies, Santa Clara, CA). Adapter ligated libraries were then hybridized 
with the biotinylated RNA baits at 65°C for 24 hours. Hybridized DNA targets of interest 
were captured using streptavidin coated magnetic beads. Targeted DNA were washed, 
eluted, and then barcoded/indexed. DNA quality was assessed using a Bioanalyzer 
(Agilent Technologies, Santa Clara, CA).  
 
NGS Sequencing and Data Analysis 
Concentrations of the indexed sample libraries were verified using quantitative 
PCR (KAPA Biosystems, Willmington, MA) and pooled together at a 1:1 ratio. Samples 
were sequenced on the HiSeq2500 instrument (Illumina, San Diego, CA) using 2x100 
paired-end reads. Sequences were aligned to the human genome reference (GRCh37 ) 
sequence, using the Burrows-Wheeler Alignment tool (BWA 0.5.9) with default 
parameters. PCR duplicates were removed using the Samtools package, and base quality 
score recalibration was performed. Local realignment and variant calling were performed 
with the Genome Analysis Toolkit (GaTK v1.3). This method enables the detection of 
low level somatic insertions and deletions. 
Low frequency (<10%) single nucleotide variants were detected using the 





al., 2011). Read coverage was gathered from the bam file data for each bed file position, 
as well as for the three possible nucleotide changes from the reference at each position. 
The reads were filtered out of the data set if < 25 mapping quality and either < 24 or <30 
base quality (depended on average read coverage for each sample). For variant read 
frequencies presented in this paper, 24 base quality was used. For each position, the 
variant read frequency of the unaffected tissue was subtracted from the variant read 
frequency for the affected tissue. Variants were kept for further analysis if the variant 
read frequency percentage was at least 1% higher in the affected tissue versus the 
unaffected tissue. 
 
Digital PCR (dPCR) 
Digital PCR was used to confirm the presence of the following somatic mutations 
in the affected tissue samples: GNAQ p.Arg183Gln, GNAQ p.Arg183Gly, and SOX10 
p.Ala183Val. DNA from matched control tissues and one negative control sample from 
peripheral blood were also evaluated for each somatic mutation. A custom TaqMan SNP 
genotyping assay (Table 3) was optimized for each variant using the QuantStudio™ 3D 
Digital PCR System (Life Technologies, Grand Island, NY). Results were analyzed using 










Table 3. Digital PCR TaqMan assay primer/probe sequences 









































 Six genes, listed in Table 1, were used in the custom NGS panel to investigate the 
molecular characteristics of isolated PWS in 12 patients. For each case, a PWS affected 
tissue sample and a contralateral normal tissue sample were analyzed. DNA extracted 
from the peripheral blood from an unaffected female was used as a negative control. 
Examples of  PWS are shown in Figure 1. Two Cases, 3 and 9, had no variants of interest 
identified in the custom NGS panel. Of the six genes in this panel, three of them had 
variants of interest in this cohort. The average NGS coverage for PWS tissue was 1,151 
reads with a range of 447-2,595 reads. The coverage for control tissue ranged from 418-
2,644 reads with an average of 1,936 reads. Variants of interest that were identified using 
the custom NGS panel were confirmed using dPCR. The dPCR method used has been 
shown to detect and quantify rare alleles with a frequency of 1% and higher (Life 
Technologies, Grand Island, NY).  
 
GNAQ Variants Confirmed in Majority of Cases 
The previously identified GNAQ p.Arg183Gln variant was identified in 9 of 12 
cases (75%), as shown in Table 4. Figure 2 shows the GNAQ p.Arg183Gln NGS trace 
and dPCR results for Case 12. Variant allele frequencies from NGS ranged from 1.73% 
to 7.42% in the PWS affected tissue. Control tissue samples ranged from 0.00-0.13%, and 





Figure 1.Case examples of port wine stains.  (A) Case 7 harbors the novel GNAQ 
p.Arg183Gly variant. (B) PWS of Case 9 tested negative for the six panel genes. 
 
 
with  the NGS data. Digital PCR results had a range of 0.85% ± 0.04 to 7.42% ± 0.04 for 
PWS tissue; while the control tissue was 0.00% ± 0.01 to 0.80% ± 1.20. The unaffected 
female sample had a variant allele frequency of 0.22% ± 0.12.  
A novel GNAQ variant p.Arg183Gly, c.547C>G was identified in Case 7 (Figure 
3). The variant was detected in 4.05% of the NGS reads for the PWS tissue. Digital PCR 
assay confirmed the results at 3.76% ± 0.37 for PWS tissue. This is a highly conserved 
region and is predicted to be damaging by Mutation Taster, Polyphen, and SIFT (sorting 
intolerant from tolerant). Both the control tissue and unaffected female were negative for 






Table 4. GNAQ p.Arg183Gln variant allele frequencies 
GNAQ  p.Arg183Gln, c.548 G>A   
Case Custom Capture (%) dPCR (% ± SD) Interpretation 
1 PWS 2.66 4.86 ± 0.60 Positive 
 
Ctrl 0.07 0.69 ± 0.97 
 2 PWS 5.80 6.35 ± 0.07  Positive 
 
Ctrl N/A 0.44 ± 0.10 
 3 PWS 0.07 0.18 ± 0.15 Negative 
 
Ctrl 0.04 0.18 ± 0.01 
 4 PWS 1.76 1.61 ± 0.37 Positive 
 
Ctrl 0.00 0.58 ± 0.41 
 5 PWS 3.31 5.44 ± 0.92 Positive 
 
Ctrl 0.00 0.10 ± 0.04 
 6 PWS 3.98 3.69 ± 0.03 Positive 
 
Ctrl 0.00 0.14 ± 0.01 
 7 PWS 0.00 0.00 Novel GNAQ 
 
Ctrl 0.00 0.00 
 8 PWS 2.99 6.15 ± 0.44 Positive 
 
Ctrl N/A 0.49 ± 0.44 
 9 PWS 0.13 0.11 ± 0.07 Negative 
 
Ctrl N/A 0.00 ± 0.06 
 10 PWS 1.73 0.85 ± 0.04 Positive* 
 
Ctrl N/A 0.28 ± 0.03 
 11 PWS 5.12 5.34 ± 0.20 Positive 
 
Ctrl N/A 0.80 ± 1.20 
 12 PWS 7.42 7.42 ± 0.04 Positive 
 
Ctrl 0 0.63  
 Unaffected 
Female 0.06 0.22 ± 0.12 Negative 
* dPCR detection limit is 1%. However, this case was interpreted as positive by 











Figure 2. Case 12 GNAQ  p.Arg183Gln NGS trace and dPCR amplification plot. (A) 
NGS trace for Case 12 showing the complement strand C>T base change. (B) dPCR 
results of Case 12. Variant alleles represented by blue, wild type alleles represented by 






Figure 3. Case 7 GNAQ  p.Arg183Gly NGS trace and dPCR amplification plot. (A) NGS 
trace showing the complement strand G>C base change. (B) dPCR results of Case 7. 
Variant alleles represented by blue, wild type alleles represented by red. Green is both 









Novel Variant Identified in SOX10 
 A novel variant, SOX10 p.Ala183Val c.548C>T, was identified in Case 8 with an 
allele frequency of 0.93% from the NGS data (Figure 4). A control tissue sample for this 
case was not available for NGS, but the wild type female had an allele frequency of 
0.16%. Many attempts were made to optimize the dPCR assay for this variant. However, 
due to the high GC content in this region, the assay failed to perform. This variant was 
not in publicly available domains such as Exome Variant Server, Exome Aggregation 
Consortium, or COSMIC. The potential effects of this variant were identified in Mutation 




 Two different RASA1 variants were identified in this cohort. Case 5 had a novel 
variant, RASA1 p.Arg579Arg c.1735C>A, identified in 1.80% of the NGS reads (Figure 
5a). Case 7 had a variant upstream from the 5’UTR region, c.-222G>A, of 1.90% in the 
PWS tissue (Figure 5b). In both cases, the control tissue and wild type female were 
negative for these variants. Confirmation with dPCR was not done on either variant 
owing to the prediction that they would not affect splicing, or translation or transcription 









Figure 4. Case 8 SOX10 p.Ala183Val NGS trace. The complement strand  for Case 8 





Figure 5. RASA1 variants of interest NGS traces. (A) NGS trace for Case 5 showing the 





Most cases of PWS occur as sporadic, isolated dermatomal lesions. Smoller and 
Rosen (1986) have proposed that lack of innervation leads to PWS. Sanchez-Carpintero 
et al. (2004) noted complex hamartomatous changes in the PWS involved multiple germ 
lines, which suggests multilineage developmental field defects might be responsible for 
the pathogenesis of PWS. In this study six genes (Table 1) were investigated for variants 
of interest in a cohort of isolated PWS cases.  
GNAQ was included to confirm the presence of a previously identified variant and 
other possible variants in this cohort of isolated PWS. Shirley et al. (2013) demonstrated 
that p.Arg183Gln c.548G>A was a somatic activating mutation in 92% of isolated PWS 
samples and 88% of patients with Sturge-Weber syndrome. The variant allele frequencies 
reported by Shirley et al. (2013) ranged from 1.0-18.1%, while this cohort ranged from 
0.85-7.42%. The difference in allele frequencies can be explained by the different 
procedures. This study used a subtractive correction method that eliminated much of the 
background noise in the NGS data (Margraf et al., 2010; Margraf et al., 2011). Using 
dPCR (~1% limit of detection) as a confirmatory assay provided a more accurate data set 
at such low levels of mosaicism. 
The novel GNAQ variant (p.Arg183Gly, c.547C>G) detected in the PWS skin of 
Case 7 is located in the same amino acid residue as the variant identified by Shirley et al. 





to the function of the GTP binding pocket of all human Gα subunits. The positive charge 
of arginine stabilizes the negative charge of the penta-coordinate phosphate intermediate, 
facilitating hydrolysis of the phosphate group and inactivates the protein (Coleman et al., 
1994). Substitution of this residue to either a polar glutamine or hydrophobic glycine 
residue, likely impairs hydrolysis, such that GNAQ remains in its active GTP-bound 
form, resulting in the observed PWS phenotype. The novel p.Arg183Gly variant has not 
been previously reported in any databases and was predicted to be damaging by multiple 
prediction algorithms.  
Among the cases positive for GNAQ mutations, there was no correlation between 
anatomical site and the mutation level. Two Cases, 3 and 9, have PWS of the limbs and 
had no variants of interest in any of the six genes used in this NGS panel. Case 11 has a 
PWS of the forearm and is positive for the GNAQ variant. There are phenotypic 
differences, as shown in Figure 1, between the positive and negative cases which may 
impact the variant frequency. Further studies will need to confirm this theory. 
Recently, Lian et al. (2014) identified additional novel somatic mutations in 
SMARCA4, EPHA3, MYB, PDGFR-β, and PIK3CA in an isolated PWS using exome 
sequencing. These genes are involved in angiogenesis, embryonic venous specification, 
and proliferation of vascular smooth muscle cells (Lian et al., 2014). Adding these genes 
to future NGS panels could help identify the genetic determinates of those cases with no 
GNAQ somatic variants. 
At the molecular level, significant ERK (extracellular signal-regulated kinases) 
activation has been observed in human embryonic kidney cells transfected with GNAQ 





2013). The mutation did not seem to activate other MAPK (mitogen-activated protein 
kinase) pathway members or the AKT (protein kinase B) signaling pathway. It is likely 
that the novel GNAQ p.Arg183Gly variant is also an activating mutation because it 
disrupts the same critical arginine residue. More recent data report the activation of ERK  
and JNK (c-Jun N-terminal kinase) in 19 of 19 PWS samples. JNK activation levels 
appeared correlated to the progressive development of PWS (Tan et al., 2014). GNAQ’s 
gain-of-function properties and how they influence the PWS phenotype will require 
further research to understand this delicate balance.   
This study also identified two novel somatic RASA1 variants (Figure 4). In these 
Cases (5 and 7), PWS involve cervicofacial dermatomes and also harbor GNAQ somatic 
variants, one of which (Case 7) has the novel p.Arg183Gly (Figure 2). No additional 
RASA1 germline mutations were found in these 2 participants. Currently, RASA1 changes 
are not seen as main genetic determinants in the pathogenesis of the studied PWS. 
Interestingly, a recent study reported that RASA1 does not seem to be involved as a 
genetic determinant of most familial PWS (Rubin et al., 2015).  
A mosaic missense mutation of SOX10 (p.Ala183Val, c.548C >T) was found in 
Case 8 (Figure 3). This patient is a woman affected by a massive PWS which involves 
more than a half of her body surface. This phenotype could be explained by an early 
disruption of the dermal vascular development. It is unclear whether a somatic mutation 
of SOX10 may have played a role in the fate specification of migrating neural crest cells 
at an early stage of development in this case.  
Of the three genes that no variants of interest were identified in, GLMN and 





familial cases of glomulovenous malformations (Brouillard et al., 2013). TIE2/TEK is 
also associated with venous malformations and has been shown to be critical to the 
survival of vascular endothelial cells (Vikkula et al., 1996). PAX3 was investigated, along 
with SOX10, because of its role during neural crest development and the hypothesis 
 that PWS could originate from neural crest cells due to their facial location. PAX3 has 
been shown to initiate neural crest specification and trigger full neural crest determination 







This study corroborates the hypothesis that GNAQ mutation represents one of the 
most important PWS pathogenic factors in the early stages of development and that other 
genetic factors may also be involved in the pathogenesis of PWS. Future directions for 
this project will be to analyze the exome data for all 12 cases using the same subtractive 
corrective method to identify additional molecular characteristics of PWS. New PWS 
cases will be analyzed using the same methods when they become available. In addition 
to that, further studies are needed to identify the cell types these mutations are happening 
in. This could likely increase the ability to see such low frequency variations if DNA was 
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